Suven Life Sciences DSMB Review: Phase 3 Masupirdine Study Advances
Suven Life Sciences (NSE: SUVEN) announced positive findings from a DSMB safety review and interim analysis of its ongoing global Phase 3 study of Masupirdine for Alzheimer's Disease Agitation.
Read article